Simon Stertzer Biography and Net Worth

Director of BioCardia


Simon H. Stertzer, M.D. has served on our board since 2002 and was previously Chairman of our board of directors. Dr. Stertzer is a Professor of Medicine, Emeritus at the Stanford University School of Medicine, Division of Cardiovascular Medicine. He was appointed Professor of Medicine at Stanford University in 1998, and became Professor Emeritus at Stanford University in 2011. Dr. Stertzer serves on the medical advisory board of Avenda Health, a private prostate cancer therapy company, and was appointed in June 2019. Dr. Stertzer is managing member of Windrock Enterprises, LLC, a real estate investment company since May 1999. He has served as a Director of Frontiere Algorithmic Design LLC, and AIVA App LLC, both software development companies, from June 2014 to October 2020. Dr. Stertzer was a founder and board member of Arterial Vascular Engineering, an angioplasty balloon and stent company that went public in 1996 and was subsequently acquired by Medtronic. He also serves as Director of AVIA App LLC since 2015. Dr. Stertzer received his Doctor of Medicine degree from New York University. He also earned a Certificat de Physiologie from the University of Paris (Sorbonne) and had a fellowship at New York University Hospital in Cardiovascular Disease. Dr. Stertzer received a Bachelor of Arts degree in Humanities from Union College.

What is Simon H. Stertzer's net worth?

The estimated net worth of Simon H. Stertzer is at least $134.47 thousand as of June 22nd, 2026. Dr. Stertzer owns 127,338 shares of BioCardia stock worth more than $134,469 as of October 5th. This net worth evaluation does not reflect any other investments that Dr. Stertzer may own. Learn More about Simon H. Stertzer's net worth.

How do I contact Simon H. Stertzer?

The corporate mailing address for Dr. Stertzer and other BioCardia executives is 320 Soquel Way, Sunnyvale, CA, 94085. BioCardia can also be reached via phone at (650) 226-0123 and via email at [email protected]. Learn More on Simon H. Stertzer's contact information.

Has Simon H. Stertzer been buying or selling shares of BioCardia?

Simon H. Stertzer has not been actively trading shares of BioCardia in the last ninety days. Most recently, on Tuesday, June 23rd, Simon H. Stertzer bought 39,000 shares of BioCardia stock. The stock was acquired at an average cost of $1.00 per share, with a total value of $39,000.00. Following the completion of the transaction, the director now directly owns 166,338 shares of the company's stock, valued at $166,338. Learn More on Simon H. Stertzer's trading history.

Who are BioCardia's active insiders?

BioCardia's insider roster includes Peter Altman (CEO), Andrew Blank (Director), Andrew Blank (Director), Bill Facteau (Director), Edward Gillis (SVP), David Mcclung (CFO), and Simon Stertzer (Director). Learn More on BioCardia's active insiders.

Are insiders buying or selling shares of BioCardia?

In the last twelve months, BioCardia insiders bought shares 26 times. They purchased a total of 169,900 shares worth more than $162,947.00. The most recent insider tranaction occured on September, 29th when CEO Peter Altman bought 1,000 shares worth more than $1,030.00. Insiders at BioCardia own 17.4% of the company. Learn More about insider trades at BioCardia.

Information on this page was last updated on 9/29/2026.

Simon H. Stertzer Insider Trading History at BioCardia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/23/2026Buy39,000$1.00$39,000.00166,338View SEC Filing Icon  
6/22/2026Buy70,200$0.92$64,584.00127,338View SEC Filing Icon  
9/19/2025Buy398,400$1.25$498,000.00591,054View SEC Filing Icon  
6/30/2025Buy72,289$2.08$150,361.12192,654View SEC Filing Icon  
3/5/2025Buy1,000$2.45$2,450.0057,138View SEC Filing Icon  
3/3/2025Buy22,753$2.30$52,331.9040,602View SEC Filing Icon  
8/2/2019Buy11,111$90.00$999,990.00View SEC Filing Icon  
12/24/2018Buy222,222$11.25$2,499,997.50View SEC Filing Icon  
11/29/2018Buy66$31.50$2,079.00View SEC Filing Icon  
11/13/2018Buy66$31.50$2,079.00View SEC Filing Icon  
11/2/2018Buy133$37.95$5,047.35View SEC Filing Icon  
10/11/2018Buy66$40.50$2,673.00View SEC Filing Icon  
9/21/2018Buy66$36.45$2,405.70View SEC Filing Icon  
9/18/2018Buy333$22.50$7,492.50View SEC Filing Icon  
3/26/2018Buy1,200$28.35$34,020.00View SEC Filing Icon  
3/22/2018Buy466$28.35$13,211.10View SEC Filing Icon  
3/1/2017Buy6,666$9.60$63,993.60View SEC Filing Icon  
1/9/2017Buy666$12.30$8,191.80View SEC Filing Icon  
12/22/2016Buy4,840$7.65$37,026.00View SEC Filing Icon  
See Full Table

Simon H. Stertzer Buying and Selling Activity at BioCardia

This chart shows Simon H. Stertzer's buying and selling at BioCardia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCardia Company Overview

BioCardia logo
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Read More

Today's Range

Now: $1.07
Low: $1.04
High: $1.08

50 Day Range

MA: $1.02
Low: $0.77
High: $1.25

2 Week Range

Now: $1.07
Low: $0.75
High: $1.80

Volume

99,640 shs

Average Volume

1,125,250 shs

Market Capitalization

$16.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62